Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Company Overview - Arcutis is a 9-year-old biotechnology company focused on medical dermatology, addressing unmet needs in the market [2] - The company was founded to innovate in the medical dermatology space, recognizing a lack of innovative solutions [2] Product Development - Arcutis's first product, ZORYVE, is a cream approved for plaque psoriasis in August 2022 [3] - The company has since received approvals for additional products, including a foam for seborrheic dermatitis in early 2024 and a different version of the cream for atopic dermatitis in mid-2024 [4] - Recently, a foam was also approved for scalp and body psoriasis, with expectations for another cream version approval for young children with atopic dermatitis [4]